查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403508

2030 年Capecitabine市场预测：按类型、适应症、分销管道、最终用户和地区进行的全球分析

Capecitabine Market Forecasts to 2030 - Global Analysis By Type (Generic and Branded), Indication (Breast Cancer, Colorectal Cancer and Other Indications),Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球Capecitabine市场规模为4.3636亿美元，预计到2030年将达到6.9613亿美元，预测期内复合年增长率为6.9%。

一种称为Capecitabine的化疗药物用于治疗多种癌症，包括腹部癌、大肠和乳癌。它以商品名 XelodaCapecitabine 市售，用作乳腺癌的单一疗法或转移性疾病的治疗，而对于大肠，它通常与放射线治疗联合用作新辅助疗法。它以其有效性、相对可控的副作用以及在提高与各种癌症作斗争的人们的生存率和生活品质方面的作用而闻名。

根据美国癌症协会的报告，2017年美国将有约135,430例大肠直肠癌新患者和50,260例死亡。

癌症患者增加

Capecitabine是一种化疗药物，广泛用于治疗多种癌症类型，包括乳癌、大肠和胃癌。口服Capecitabine他滨，加上其在体内转化为活性形式的能力，使其成为一种方便而有效的癌症治疗选择。癌症患者人数不断增加，需要增加Capecitabine等治疗方案的可及性，从而导致市场增长，作为应对全球癌症患者不断增长趋势的重要治疗方案。它正在被拖曳。

治疗费用增加

随着包括药品成本在内的医疗保健成本的增加，负担能力已成为患者和医疗保健系统关注的问题。Capecitabine是一种用于治疗多种癌症的化疗药物，价格昂贵且难以获得，这可能会影响患者的医嘱遵从性和医疗保健预算限制。个人和医疗保健提供者日益增加的经济负担可能会限制这种药物的获得，阻碍其普及，并影响癌症患者的治疗选择。

扩大口服化疗的接受度

作为一种口服药物，与标准静脉注射相比，Capecitabine在治疗期间为患者提供了更大的便利性、弹性，并提高了生活品质。此外，它需要最少的医院就诊次数，并且可以在家中自行管理，从而简化了医疗服务并降低了成本。此外，癌症治疗中向口服化疗的转变代表了一种进化的变化。Capecitabine是一种口服製剂，引领了这一趋势，并透过满足患者对更方便、更容易获得的治疗选择的需求而在市场上立足。这将促进市场成长。

缺乏熟练的专业人员

化疗，包括Capecitabine等药物，需要专门的知识和训练。缺乏熟练的肿瘤科医生、护士和药剂师来管理和监督化疗可能会阻碍Capecitabine的有效使用和处方。缺乏熟练的专业人员可能会导致治疗效果不佳、损害患者的治疗效果并限制药物的供应。

COVID-19 的影响

COVID-19 大流行对整个经济产生了显着影响。受疫情影响，多家原料药生产厂关闭，原料药业务面临许多挑战。其中包括供应链中断、原材料和包装材料采购问题以及劳动力短缺导致的营运能力下降。然而，随着COVID-19情势的恶化，几种药品的市场激增，增加了对生产相关活性原料药的需求。

预计乳癌细分市场在预测期内将是最大的

据估计，乳癌所占比例最大。Capecitabine是一种口服化疗药物，广泛用于治疗各个阶段和类型的乳癌，包括转移性乳癌和手术后的辅助性治疗。由于其有效抑制癌细胞增生且口服给药方便，成为乳癌治疗方法的首选。作为联合治疗或单一疗法的一部分，Capecitabine在靶向乳癌细胞方面的功效已经确立了其重要性，并巩固了其作为满足乳癌患者治疗需求的关键组成部分的地位。

预计胶囊细分市场在预测期内复合年增长率最高。

预计胶囊细分市场在预测期内将出现良好的成长。Capecitabine通常以胶囊形式提供，为接受化疗的患者提供了方便的口服给药途径。胶囊含有活性药物，可以精确剂量且易于摄取。此外，Capecitabine的胶囊型态为医疗保健专业人员和患者提供了一种方便有效的治疗各种癌症的选择，进一步巩固了其在製药行业的地位，这极大地有助于我们在市场上的占有率。

比最大的地区

由于癌症的流行和弱势老年人口，亚太地区在预测期内占据了最大的市场占有率。此外，庞大的人口基数，尤其是中国、印度和日本等国家，拥有大量患者，推动市场扩张。此外，製药公司之间的合作伙伴关係、政府加强癌症治疗的倡议以及具有成本效益的学名药的推出进一步支持了Capecitabine在亚太地区的供应和普及。

复合年增长率最高的地区：

北美是主要非专利药公司的所在地，由于政府倡议和特殊社区的增加，预计在预测期内将实现报酬率增长。此外，该地区强大的医疗基础设施、先进的研究设施和高癌症发病率促使Capecitabine在治疗各种癌症类型（包括乳癌和大肠）中得到大量使用。有利的报销政策和医疗保健投资的增加支持了Capecitabine的可及性，使北美成为塑造Capecitabine利用和市场扩张格局的关键地区。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球Capecitabine市场：依药物类型

  • 非专利的
  • 品牌

第六章全球Capecitabine市场：依适应症分类

  • 乳癌
  • 大肠直肠癌
  • 其他适应症

第七章全球Capecitabine市场：按分销管道

  • 医院药房
  • 零售药房
  • 网路药房

第八章全球Capecitabine市场：按剂型

  • 胶囊
  • 药片

第 9 章Capecitabine全球市场：依最终用户分类

  • 医院
  • 专业中心
  • 居家护理
  • 其他最终用户

第十章全球Capecitabine市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Sanofi
  • GSK plc
  • Pfizer Inc.
  • Novartis AG
  • Lilly
  • Bayer AG
  • Merck & Co., Inc.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Alkem Labs Ltd
  • Lupin
  • Armas Pharmaceuticals, Inc
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
Product Code: SMRC24733

According to Stratistics MRC, the Global Capecitabine Market is accounted for $ 436.36 million in 2023 and is expected to reach $ 696.13 million by 2030 growing at a CAGR of 6.9% during the forecast period. A chemotherapy drug called capecitabine is used to treat a variety of cancers, such as abdomen, colorectal, and breast cancers. It is commercialized under the trade name of XelodaCapecitabine is used as a monotherapy or metastatic treatment for breast cancer, while in cases of colorectal cancer, the drug is mostly used as neoadjuvant therapy with radiation. It is known for its efficacy, relatively manageable side effects, and its role in improving survival rates and quality of life for individuals battling various forms of cancer.

According to the American Cancer Society report, in 2017 about 135,430 new cases and 50,260 deaths were estimated due to colon and rectum cancer in the U.S.

Market Dynamics:

Driver:

Rising in cancer cases

Capecitabine, a chemotherapy medication, is widely used in the treatment of multiple cancer types, including breast, colorectal, and gastric cancers. Its oral administration, coupled with its ability to convert into an active form within the body, makes it a convenient and potent option for cancer therapy. The expanding pool of cancer patients necessitates increased access to treatment options like Capecitabine, thereby driving its market growth as a crucial therapeutic choice in combating the rising tide of cancer cases worldwide.

Restraint:

Increasing treatment costs

As healthcare expenses rise, including medication costs, affordability becomes a concern for patients and healthcare systems. Capecitabine, a chemotherapy drug used to treat various cancers, might become less accessible due to its higher cost, impacting patient adherence and healthcare budget constraints. The increasing financial burden on individuals and healthcare providers limits access to this medication, potentially hindering its widespread use and affecting treatment options for cancer patients.

Opportunity:

Growing acceptance of oral chemotherapy

As an oral medication, capecitabine offers patients more convenience, flexibility, and a better quality of life throughout treatment than standard intravenous chemotherapy. In addition, minimal hospital visits are required, and self-administration at home is an option, which simplifies healthcare delivery and lowers expenses. Moreover, the change in cancer treatment towards oral chemotherapy is indicative of an evolutionary change. Capecitabine, with its oral formulation, is leading this trend and has positioned itself well in the market by satisfying patient demand for more convenient and accessible treatment alternatives. Thereby, it will enhance market growth.

Threat:

Lack of Skilled Professionals

Administering chemotherapy, including drugs like Capecitabine, requires specialised knowledge and training. The shortage of proficient oncologists, nurses, and pharmacists capable of managing and overseeing chemotherapy procedures could impede the effective use and prescription of Capecitabine. This dearth of skilled professionals might result in suboptimal treatment, compromising patient outcomes, and potentially limiting the drug's utilization.

COVID-19 Impact

The COVID-19 pandemic had a notable effect on the overall economy. The pandemic caused many API manufacturing plants to close during this time, which presented the API business with a number of difficulties. Some of these were supply chain disruptions, issues in locating raw materials and packaging materials, and decreased operational capacity as a result of labour shortages. But when the COVID-19 situation worsened, there was a surge in the market for several medications, which raised the need for production-related APIs.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is estimated to hold the largest share. Capecitabine, an oral chemotherapy drug, is widely utilized in various stages and types of breast cancer, including metastatic breast cancer and adjuvant therapy after surgery. Its effectiveness in inhibiting cancer cell growth and its oral administration convenience make it a preferred choice in breast cancer treatment regimens. As part of combination therapies or standalone treatment, Capecitabine's efficacy in targeting breast cancer cells has established its significance, cementing its position as a pivotal component in addressing the therapeutic needs of patients battling breast cancer.

The capsules segment is expected to have the highest CAGR during the forecast period

The capsules segment is anticipated to have lucrative growth during the forecast period. Capecitabine is commonly available in capsule form, offering a convenient oral administration route for patients undergoing chemotherapy. The capsules contain the active drug, facilitating precise dosing and ease of intake. Moreover, the capsule form of Capecitabine contributes substantially to its market presence, providing both medical professionals and patients with a convenient and efficient option for managing various cancer types, further solidifying its role in the pharmaceutical landscape.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the prevalence of cancer and vulnerable geriatric population. Additionally, the region's large population base, particularly in countries like China, India, and Japan, offers a substantial patient pool, fostering market expansion. Moreover, collaborations between pharmaceutical companies, government initiatives to enhance cancer care, and the introduction of cost-effective generic versions further propel the accessibility and adoption of Capecitabine across the Asia-Pacific region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to the presence of key generic pharmaceutical companies in this region and the rise in government initiatives and special communities. Moreover, the region's robust healthcare infrastructure, advanced research facilities, and high prevalence of cancer contribute to the substantial utilisation of Capecitabine in the treatment of various cancer types, including breast and colorectal cancers. Favourable reimbursement policies and increasing investments in healthcare support the accessibility of Capecitabine, making North America a pivotal region in shaping the landscape of Capecitabine utilisation and market expansion.

Key players in the market:

Some of the key players in the Capecitabine Market include F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi, GSK plc, Pfizer Inc., Novartis AG, Lilly, Bayer AG, Merck & Co., Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Alkem Labs Ltd, Lupin, Armas Pharmaceuticals, Inc, Dr. Reddy's Laboratories Ltd., Cipla Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC and Intas Pharmaceuticals Limited.

Key Developments:

In December 2022, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer. This product launch may help the company to enhance their product portfolio and enhance business revenue.

In February 2021, Dr Reddy's Laboratories announced the launch of Capecitabine Tablets, USP, in the U.S. market. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). This product launch helped the company to enhance their product portfolio and enhance their business revenue.

Drug Types Covered:

  • Generic
  • Branded

Indications Covered:

  • Breast Cancer
  • Colorectal Cancer
  • Other Indications

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Drug Formulations Covered:

  • Capsules
  • Tablets

End Users Covered:

  • Hospitals
  • Speciality Centres
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Capecitabine Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Generic
  • 5.3 Branded

6 Global Capecitabine Market, By Indication

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Colorectal Cancer
  • 6.4 Other Indications

7 Global Capecitabine Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacy
  • 7.3 Retail Pharmacy
  • 7.4 Online Pharmacy

8 Global Capecitabine Market, By Drug Formulation

  • 8.1 Introduction
  • 8.2 Capsules
  • 8.3 Tablets

9 Global Capecitabine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Speciality Centres
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Capecitabine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 F. Hoffmann-La Roche Ltd.
  • 12.2 Teva Pharmaceutical Industries Ltd.
  • 12.3 Mylan N.V.
  • 12.4 Sanofi
  • 12.5 GSK plc
  • 12.6 Pfizer Inc.
  • 12.7 Novartis AG
  • 12.8 Lilly
  • 12.9 Bayer AG
  • 12.10 Merck & Co., Inc.
  • 12.11 Aurobindo Pharma
  • 12.12 Sun Pharmaceutical Industries Ltd.
  • 12.13 Alkem Labs Ltd
  • 12.14 Lupin
  • 12.15 Armas Pharmaceuticals, Inc
  • 12.16 Dr. Reddy's Laboratories Ltd.
  • 12.17 Cipla Inc.
  • 12.18 Fresenius SE & Co. KGaA
  • 12.19 Hikma Pharmaceuticals PLC
  • 12.20 Intas Pharmaceuticals Limited

List of Tables

  • Table 1 Global Capecitabine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 4 Global Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 5 Global Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 6 Global Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 7 Global Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 8 Global Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 9 Global Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 10 Global Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 11 Global Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 12 Global Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 13 Global Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 14 Global Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 15 Global Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 16 Global Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 17 Global Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 18 Global Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 19 Global Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 20 Global Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 21 North America Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 22 North America Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 23 North America Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 24 North America Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 25 North America Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 26 North America Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 27 North America Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 28 North America Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 29 North America Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 North America Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 31 North America Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 32 North America Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 33 North America Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 34 North America Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 35 North America Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 36 North America Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 North America Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 North America Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 39 North America Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 40 North America Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 41 Europe Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 42 Europe Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 43 Europe Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 44 Europe Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 45 Europe Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 46 Europe Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 47 Europe Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 48 Europe Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 49 Europe Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 50 Europe Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 51 Europe Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 52 Europe Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 53 Europe Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 54 Europe Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 55 Europe Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 56 Europe Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 57 Europe Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 58 Europe Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 59 Europe Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 60 Europe Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 Asia Pacific Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Asia Pacific Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 63 Asia Pacific Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 64 Asia Pacific Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 65 Asia Pacific Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 66 Asia Pacific Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 67 Asia Pacific Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 68 Asia Pacific Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 69 Asia Pacific Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 70 Asia Pacific Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 71 Asia Pacific Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 72 Asia Pacific Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 73 Asia Pacific Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 74 Asia Pacific Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 75 Asia Pacific Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 76 Asia Pacific Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 77 Asia Pacific Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 78 Asia Pacific Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 79 Asia Pacific Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 80 Asia Pacific Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 81 South America Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 South America Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 83 South America Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 84 South America Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 85 South America Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 86 South America Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 87 South America Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 88 South America Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 89 South America Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 90 South America Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 91 South America Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 92 South America Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 93 South America Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 94 South America Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 95 South America Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 96 South America Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 South America Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 98 South America Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 99 South America Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 100 South America Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 Middle East & Africa Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 Middle East & Africa Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 103 Middle East & Africa Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 104 Middle East & Africa Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 105 Middle East & Africa Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 106 Middle East & Africa Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 107 Middle East & Africa Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 108 Middle East & Africa Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 109 Middle East & Africa Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 110 Middle East & Africa Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 111 Middle East & Africa Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 112 Middle East & Africa Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 113 Middle East & Africa Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 114 Middle East & Africa Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 115 Middle East & Africa Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 116 Middle East & Africa Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 117 Middle East & Africa Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 118 Middle East & Africa Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 119 Middle East & Africa Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 120 Middle East & Africa Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)